These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15834972)

  • 61. Researchers identify better hepatitis C treatment for people with HIV.
    J Investig Med; 2004 Nov; 52(7):431-2. PubMed ID: 15655871
    [No Abstract]   [Full Text] [Related]  

  • 62. Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients.
    Cinelli R; Di Gennaro G; Nasti G; Tedeschi R; Dal Maso L; Canzonieri V; Balestreri L; Fedele P; Tirelli U
    AIDS; 2004 Apr; 18(7):1079-80. PubMed ID: 15096816
    [No Abstract]   [Full Text] [Related]  

  • 63. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.
    ; ;
    Dig Liver Dis; 2010 Feb; 42(2):81-91. PubMed ID: 19748329
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Study results presented on interferon/ribavirin combination therapy.
    AIDS Read; 2001 Aug; 11(8):398. PubMed ID: 11570262
    [No Abstract]   [Full Text] [Related]  

  • 65. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
    Medrano J; Barreiro P; Resino S; Tuma P; Rodríguez V; Vispo E; Labarga P; Madejón A; García-Samaniego J; Jiménez-Nácher I; Martín-Carbonero L; Soriano V
    Clin Infect Dis; 2009 Nov; 49(9):1397-401. PubMed ID: 19814621
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recent advances in the treatment of HIV/HBV and HIV/HCV co-infection.
    Masgala A; Bonovas S; Nikolopoulos GK
    Mini Rev Med Chem; 2012 Aug; 12(9):890-904. PubMed ID: 22530578
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Very few hepatitis trials recruiting.
    AIDS Patient Care STDS; 1998 Apr; 12(4):319-20. PubMed ID: 11361965
    [No Abstract]   [Full Text] [Related]  

  • 68. New paradigms in the management of hepatitis C virus co-infections.
    Sherman KE
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4 Suppl 1():S10-6. PubMed ID: 17235280
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
    Pár A; Pár G
    Orv Hetil; 2008 Jul; 149(28):1329-32. PubMed ID: 18617461
    [No Abstract]   [Full Text] [Related]  

  • 70. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin.
    Bongiovanni M; Ranieri R; Ferrero S; Casanova F; Monforte Ad
    AIDS; 2006 Oct; 20(15):1989-90. PubMed ID: 16988527
    [No Abstract]   [Full Text] [Related]  

  • 71. Editorial comment: triple infection with HIV and hepatitis B and C viruses--lesson in combination therapy.
    Dore GJ
    AIDS Read; 2004 Jul; 14(7):392. PubMed ID: 15282869
    [No Abstract]   [Full Text] [Related]  

  • 72. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
    Urganci N; Gulec S; Dogan S; Nuhoglu A
    Int J Infect Dis; 2006 Nov; 10(6):453-7. PubMed ID: 17000127
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Report of three cases of hyperlactacidemiae/lactic acidosis after treatment of hepatitis C with pegylated interferon and ribavirin in HIV coinfected patients].
    Montes Ramírez ML; Rodríguez Zapata M
    Rev Clin Esp; 2002 Oct; 202(10):543-5. PubMed ID: 12361553
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment of human papillomavirus with peg-interferon alfa-2b and ribavirin.
    Pavan MH; Velho PE; Vigani AG; Gonçalves FL; Aoki FH
    Braz J Infect Dis; 2007 Jun; 11(3):383-4. PubMed ID: 17684645
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HIV and hepatitis C virus coinfection: bad bedfellows.
    Schooley RT
    Top HIV Med; 2005; 13(4):112-6. PubMed ID: 16304454
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV and hepatitis C co-infection: acute HCV therapy.
    Boesecke C; Vogel M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):459-64. PubMed ID: 22001891
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Meeting notes from ICAAC. Choosing the right HCV-coinfected patients to treat.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):7-8. PubMed ID: 15717375
    [No Abstract]   [Full Text] [Related]  

  • 80. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy.
    Landau A; Batisse D; Piketty C; Jian R; Kazatchkine MD
    AIDS; 2000 Aug; 14(12):1857-8. PubMed ID: 10985327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.